Products and
Pipeline

Exkivity (Mobocertinib)

EXKIVITY^® (mobocertinib) is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Visit Exkivity Website

www.exkivity.com

Prescribing Information

Download PDF

Alunbrig (Brigatinib)

ALUNBRIG^® (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Visit HCP Website

www.alunbrig.com/hcp

Prescribing Information

Download PDF

Ninlaro (Ixazomib)

NINLARO^® (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Limitations of Use: NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials.

Visit Ninlaro Website

www.ninlaro.com

Prescribing Information

Download PDF

Velcade (bortezomib)

VELCADE^® (bortezomib) is approved for the treatment of adults with multiple myeloma (a cancer of the plasma cells). VELCADE is also approved for the treatment of adults with mantle cell lymphoma (a cancer of the lymph nodes).

Visit Velcade Website

www.velcade.com

Prescribing Information

Download PDF